Patents Examined by Stacy B. Chen
  • Patent number: 11123708
    Abstract: Material complexes that capture biologicals and methods of synthesizing and using such complexes composed of fluid-insoluble material and a receptor are provided herewith. The fluid-insoluble material has reactive functionality on its surface, including hydroxyl, amino, mercapto or eposy functionality material. The material can be agarose, sand, textile, or any combination thereof. The receptor is selected from the group consisting of mono-and poly-saccharides, heparin, or any combination thereof. Also provide are methods whereby releasing the captured biologicals and is controllable.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: September 21, 2021
    Assignee: RAN Biotechnologies, Inc.
    Inventor: Roger A. Nassar
  • Patent number: 11117955
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the ZIKV for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: September 14, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, William Olson, Peter Mason
  • Patent number: 11117954
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: September 14, 2021
    Assignee: HUMABS BIOMED SA
    Inventor: Davide Corti
  • Patent number: 11110162
    Abstract: The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccine composition for use in a method of preventing or treating a Zika virus disease.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: September 7, 2021
    Assignee: THEMIS BIOSCIENCE GMBH
    Inventors: Erich Tauber, Sabrina Schrauf, Matthias Müllner, Katrin Ramsauer, Angelika Irmler, Patrick Csar
  • Patent number: 11104915
    Abstract: A process for assaying viral vector manufactured by large-scale viral vector manufacturing processes to assure the resulting vector has acceptable purity and potency. The process entails three different types of assays, each one of which is optionally useful on a stand-alone basis, and which together provide the first system able to assure the quality of viral vector produced by large-scale vector manufacturing processes.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 31, 2021
    Assignee: Trizell Ltd.
    Inventors: Nigel Parker, Hanna P. Lesch, Jenni Mykkanen, Sara Paulo, Minna Hassinen, Robert Shaw
  • Patent number: 11103575
    Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 31, 2021
    Assignee: The New York Blood Center, Inc.
    Inventors: Lanying Du, Fang Li, Shibo Jiang, Yusen Zhou
  • Patent number: 11103572
    Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: August 31, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
  • Patent number: 11099180
    Abstract: The disclosure concerns a method and kits for measurement of an analyte in a microparticle-based analyte-specific binding assay. In the assay, the microparticles are coated with the first partner of a binding pair, mixing the coated microparticles and at least two analyte-specific binding agents, each conjugated to the second partner of the binding pair, and a sample suspected of containing the analyte. The second partner of the binding pair is bound to each of the analyte-specific binding agents via a linker comprising from 12 to 30 ethylene glycol units (PEG 12 to 30), thereby binding the analyte via the conjugated analyte-specific binding agents to the coated microparticles. The method also entails separating the microparticles having the analyte bound via the binding pair and the analyte-specific binding agent from the mixture and measuring the analyte bound to the microparticles.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: August 24, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ralf Bollhagen, Barbara Upmeier, Werner Naser, Toralf Zarnt
  • Patent number: 11091518
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Ebolavirus glycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against Ebolavirus are disclosed. Method of preventing Ebolavirus and methods of treating individuals infected with Ebolavirus are disclosed. Consensus Ebolavirus proteins are disclosed.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 17, 2021
    Assignees: The Trustees of the University of Pennsylvania, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Ami Patel, Jian Yan
  • Patent number: 11071783
    Abstract: The invention is directed to HIV-1 neutralizing antibodies and methods for their uses.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: July 27, 2021
    Assignees: DUKE UNIVERSITY, UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody, LaTonya Williams, Kevin J. Wiehe, Gilad Adi Ofek
  • Patent number: 11065327
    Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: July 20, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
  • Patent number: 11058764
    Abstract: Embodiments include a method of using inactivated human cold coronaviruses (HCoVs) particularly HCoV-299E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1, alone or as a booster, for the immunization against SARS-CoV-2 infections. Vaccine embodiments further comprise HCoV virus envelope subunits which may be in the form of virus-like spheroids (VLS).
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: July 13, 2021
    Inventors: Timothy S. Moore, Cullen Thomas Moore
  • Patent number: 11058759
    Abstract: Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: July 13, 2021
    Assignee: Medigen, Inc.
    Inventors: Peter Pushko, Irina Tretyakova
  • Patent number: 11059883
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 13, 2021
    Assignee: VISTERRA, INC.
    Inventors: Luke Robinson, Zachary Shriver, James R. Myette, Gregory Babcock, Karthik Viswanathan
  • Patent number: 11053283
    Abstract: The present invention relates to a method for removal of large contaminants, such as virus, in a chromatographic process for purification of a target molecule, preferably monoclonal antibodies, mAbs, by using a specifically designed chromatographic bead having a thin outer layer and a core functionalized with a ligand adsorbing the mAbs or parts thereof.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: July 6, 2021
    Assignee: Cytiva BioProcess R&D AB
    Inventors: Jean-Luc Maloisel, Ola Lind, Bjorn Noren, Ronnie Palmgren
  • Patent number: 11045496
    Abstract: The present invention describes a method for treating cancer comprising adoptive transfer of tumor antigen specific CD8+ T cells and an oncolytic virus vaccine targeting the same antigen.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 29, 2021
    Assignee: McMaster University
    Inventors: Yonghong Wan, Scott Walsh, Lan Chen, Omar Salem, Boris Simovic
  • Patent number: 11046959
    Abstract: Disclosed herein, are compositions and methods for the treatment of human immunodeficiency virus infection. The compositions comprise engineered transcription activator like effector nucleases (TALENs) comprising a TALE DNA binding domain flanked by two spacer sequences, and a Fokl nuclease catalytic domain. Also, described herein, are methods of using TALENs to cleave nucleic acids; and methods of administering the TALENs to subjects at risk for or having an HIV infection.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 29, 2021
    Assignee: The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas
    Inventors: Martin R. Schiller, Christy L. Strong
  • Patent number: 11034732
    Abstract: Methods and compositions are provided that can be used to modify the assembly activating protein (AAP)-dependence of an adeno-associated virus (AAV).
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: June 15, 2021
    Assignees: Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.
    Inventors: Luk H. Vandenberghe, Anna Claire Maurer
  • Patent number: 11034730
    Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 15, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DU CAMBODGE
    Inventors: Frederic Tangy, Anavaj Sakuntabhai, Etienne Simon-Loriere, Claude Roth, Philippe Buchy
  • Patent number: 11034731
    Abstract: Stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions including the polypeptides, and uses thereof for the prevention and/or treatment of RSV infection are described.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: June 15, 2021
    Inventors: Johannes Petrus Maria Langedijk, Polina Furmanova Hollenstein